Edgewise Therapeutics

Historical price data

Edgewise Therapeutics is on a mission to develop transformative oral therapies for rare muscle disorders by targeting the fundamental biology of muscle contraction. Its core achievement is the rapid clinical advancement of EDG-5506, a selective myosin modulator now in Phase 2/3 trials for Becker muscular dystrophy and Phase 2 for Duchenne muscular dystrophy. The company's strategy leverages a proprietary platform to address a critical pathophysiological driver—excessive muscle contraction—across multiple myopathies. This focused approach has established Edgewise as a leader in the neuromuscular space, backed by strong investor confidence and a clear regulatory pathway.

Proprietary platform for discovering oral, small molecule inhibitors that selectively modulate skeletal muscle myosin to protect muscles from contraction-induced injury, applicable across a range of rare genetic myopathies.

Edgewise's oral myosin modulator is first-in-class with no direct mechanistic competitors. It competes with standard corticosteroids (ineffective long-term) and complements genetic therapies (mutation-specific and invasive). Its primary competitive advantages are its novel protective mechanism, compelling early biomarker data, and the patient convenience of an oral drug.